Neonatal withdrawal syndrome after chronic maternal consumption of 4-methylethcathinone

Forensic Science International

Volumn 245, Issue , 2014, Pages e33-e35

  Pichini, Simona ^a   Rotolo, Maria Concetta ^a   García, Jordi ^b   Girona, Noelia ^c   Leal, Lorna ^c   García Algar, Oscar ^b   Pacifici, Roberta ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

Author keywords

4 Methylethcathinone; Hair testing; Meconium; Neonatal withdrawal syndrome

Indexed keywords

4 METHYLETHCATHINONE; CENTRAL STIMULANT AGENT; METHADONE; UNCLASSIFIED DRUG; 4-METHYLETHCATHINONE; AMPHETAMINE DERIVATIVE; DESIGNER DRUG; PROPIOPHENONE DERIVATIVE;

ARTICLE; CASE REPORT; DRUG EXPOSURE; DRUG USE; HOSPITAL DISCHARGE; HUMAN; IRRITABILITY; LIQUID CHROMATOGRAPHY; MALE; MECONIUM; MUSCLE HYPERTONIA; NEONATAL WITHDRAWAL SYNDROME; NERVOUSNESS; NEWBORN; PATHOLOGICAL CRYING; PHYSICAL EXAMINATION; PREGNANCY; SMOKING; TANDEM MASS SPECTROMETRY; WITHDRAWAL SYNDROME; COMPLICATION; DRUG DEPENDENCE; FEMALE; FETOMATERNAL TRANSFUSION; NEONATAL ABSTINENCE SYNDROME;

AMPHETAMINES; DESIGNER DRUGS; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PROPIOPHENONES; SUBSTANCE-RELATED DISORDERS;

EID: 84912031768     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.10.027     Document Type: Article

References (18)

1. Hill S.L., Thomas S.H. Clinical toxicology of newer recreational drugs. Clin. Toxicol. (Phila). 2011, 49:705-719.
2. Sutter M.E., Chenoweth J., Albertson T.E. Alternative drugs of abuse. Clin. Rev. Allergy Immunol. 2014, 46:3-18.
3. European Drug Report 2013: Trends and developments 2013, May, EMCDDA, Lisbon, (accessed 11.08.14). http://www.emcdda.europa.eu/publications/edr/trends-developments/2013.
4. Miotto K., Striebel J., Cho A.K., Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013, 132:1-12.
5. Tekulve K., Alexander A., Tormoehlen L. Seizures associated with synthetic cathinone exposures in the pediatric population. Pediatr. Neurol. 2014, 51:67-70.
6. German C.L., Fleckenstein A.E., Hanson G.R. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life. Sci. 2014, 9:2-8.
7. Caudevilla-Gálligo F., Ventura M., Indave B.I., Fornís I. Presence and composition of cathinone derivatives in drug samples taken from a drug test service in Spain (2010-2012). Hum. Psychopharmacol. 2013, 28:341-344.
8. Kaltenbach K., Finnegan L.P. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav. Toxicol. Teratol. 1986, 8:353-355.
9. Pichini S., Gottardi M., Marchei E., Svaizer F., Pellegrini M., Rotolo M.C., Garcia-Algar O., Pacifici R. Rapid extraction, identification and quantification of drugs of abuse in hair by immunoassay and ultra-performance liquid chromatography tandem mass spectrometry. Clin. Chem. Lab. Med. 2014, 52:679-686.
10. Pichini S., Pacifici R., Pellegrini M., Marchei E., Pérez-Alarcón E., Puig C., Vall O., García-Algar O. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of opiates and cocaine in meconium. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003, 794:281-292.
11. Pichini S., Pacifici R., Pellegrini M., Marchei E., Lozano J., Murillo J., Vall O., García-Algar O. Development and validation of a high-performance liquid chromatography-mass spectrometry assay for determination of amphetamine, methamphetamine, and methylenedioxy derivatives in meconium. Anal. Chem. 2004, 76:2124-2132.
12. Jankovics P., Varadi A., Tölgyesi L., Lohner S., Németh-Palotás J., Koszegi-Szalai H. Identification and characterization of the new designer drug 4'-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs. Forensic Sci. Int. 2011, 210:213-220.
13. Cleary B.J., Eogan M., O'Connell M.P., Fahey T., Callagher P.J., Clarke T., White M.J., McDermott C., O'Sullivan A., Carmody D., Gleeson J., Murphy D.J. Methadone and perinatal outcomes: a prospective cohort study. Addiction 2012, 107:1482-1492.
14. Coyle M.G., Salisbury A.L., Lester B.M., Jones H.E., Lin H., Graf-Rohrmeister K., Fischer G. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012, 107:63-73.
15. Brogly S.B., Saia K.A., Walley A.Y., Du H.M., Sebastiani P. Prenatal buprenorphin versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am. J. Epidemiol. 2014, 180:673-686.
16. Jansson L.M., Di Pietro J.A., Elko A., Williams E.L., Milio L., Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend. 2012, 122:213-2199.
17. Cleary B.J., Donnelly J., Strawbridge J., Gallagher P.J., Fahey T., Clarke M., Murphy D.J. Methadone dose and neonatal abstinence syndrome - systematic review and meta-analysis. Addiction 2010, 105:2071-2084.
18. Garcia-Algar O., Florensa L., Sanchez E., Minoves D., Esteban E., Mur A. Methadone and neonatal thrombocytosis. Pediatr. Hematol. Oncol. 2002, 19:193-195.